cardiac perforation News
-
Experience with BioTrace Medical’s Tempo Temporary Pacing Lead in Mitral Valve Surgeries Presented at Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting
BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo Temporary Pacing Lead was featured in a patient case series presented at the Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting and Workshops, taking place virtually April 24-27. The series titled “A Case Series of the BioTrace Medical Tempo ...
-
BioTrace Medical Announces Key Events Featuring Tempo Temporary Pacing Lead at TCT 2019
BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) conference, which will take place September 25-29 in San Francisco. The company’s Tempo Temporary Pacing Lead will be featured in a breakfast symposium titled “Keeping the Rhythm with the ...
-
BioTrace Medical’s Tempo Lead Obtains CE Mark for Safe and Secure Temporary Intracardiac Pacing
BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s Tempo Lead has obtained CE Mark certification in Europe for use in cardiac procedures requiring temporary intracardiac pacing. BioTrace Medical’s Tempo Temporary Pacing Lead is designed for safer, more secure and stable pacing to reduce intraprocedural complications, ...
-
BioTrace Medical’s Tempo Lead Obtains CE Mark for Safe and Secure Temporary Intracardiac Pacing
BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s Tempo Lead has obtained CE Mark certification in Europe for use in cardiac procedures requiring temporary intracardiac pacing. BioTrace Medical’s Tempo Temporary Pacing Lead is designed for safer, more secure and stable pacing to reduce intraprocedural complications, ...
-
FDA Approves BAVENCIO (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma
BAVENCIO is the first anti-PD-L1 in combination with axitinib approved by FDA for first-line treatment of patients with advanced renal cell carcinoma (RCC) Phase III study showed combination significantly lowered risk of disease progression or death by 31% and extended progression-free survival by 5.4 months for patients with advanced RCC compared with sunitinib Combination approved based on ...
By Siemens AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you